Karakterisasi Peptida Nterm-34 kDa Protein Saliva Nyamuk Aedes aegypti sebagai Kandidat Antigen Biomarker Risiko Transmisi Virus Dengue Secara In Silico

Yunita Armiyanti, Nizar Fiska Bayu Agustian, Sheilla Rachmania


Recently, a new biomarker of mosquito bite has been developed using human antibody response to mosquito salivary protein. One of the proteins that has been tested is salivary protein 34-kDa which has been refined to Nterm-34 kDa peptide. This study aimed to characterize Nterm-34 kDa salivary peptide as a potential antigen biomarker to asses Dengue virus transmission risk. The sequence Nterm-34 kDa was analyzed using several software to predict the characteristic of the peptide. BLASTP from Vectorbase and NCBI wa used to check the specificity of the peptide. IBIVU Praline was used to do multiple sequence alignment. IEDB (Bepipred and Kolaskar & Tongaonkar antigenicity prediction) was used to predict epitopes and antigenic properties, and lastly, ProtParam was used to predict physicochemical properties. The result showed that Nterm-34 kDa salivary peptide is specific to the  Aedes aegypti mosquito at the species level and has low conservation compared to other proteins in Aedes aegypti 34-kDa salivary protein family. Nterm-34 kDa is predicted to be antigenic and one of the epitopes. Nterm-34 kDa salivary peptide is predicted to have a molecular weight of 2,092 kDa, unstable, and hydrophilic. In conclusion, Nterm-34 kDa salivary peptide is predicted to have potential as an antigen biomarker for Dengue virus transmission.


Nterm-34 kDa, salivary protein, Aedes aegypti, antigen, biomarker, in silico


Brady, O. J., P. W. Gething, S. Bhatt, J. P. Messina, J. S. Brownstein, A. G. Hoen, et al. 2012. Refining the global spatial limits of Dengue virus transmission by evidence-based consensus. PLOS Neglected Tropical Diseases. 6(8): 1-15.

Bhatt, S., P. W. Gething, O. J. Brady, J. P. Messina, A. W. Farlow, C. L. Moyes, et al. 2013. The global distribution and burden of dengue. Nature. 496(7446): 504–507.

Kenea, O., M. Balkew, H. Tekie, T. Gebre-Michael, W. Deressa, E. Loha, et al. 2017. Comparison of Two Adult Mosquito Sampling Methods with Human Landing Catches in South-Central Ethiopia. Malaria Journal. 16(1): 1–15.

Garjito, T. A., L. Susanti, Mujiyono, M. T. Prihatin, D. Susilo, S. S. Nugroho, Mujiyanto, R. A. Wigati, et al. 2021. Assessment of Mosquito Collection Methods for Dengue Surveillance. Frontiers in Medicine. 8(6859926): 1-8.

Sagna, A. B., M. C.Yobo, E. E. Ndille, F. Remoue. 2018. New immuno-epidemiological biomarker of human exposure to Aedes vector bites: From concept to applications †. Tropical Medicine and Infectious Disease. 3(3): 1-14

Montero, S. B., Gabrieli, P., Montarsi, F., Borean, A., Capelli, S., de Silvestro, G., Forneris, F., Pombi, et al. 2020. IgG nntibody responses to the Aedes albopictus 34k2 salivary protein as novel candidate marker of human exposure to the tiger mosquito. Frontiers in Cellular and Infection Microbiology. 10(July): 1–12Kenea, O., M. Balkew, H. Tekie, T. Gebre-Michael, W. Deressa, E. Loha, B. Lindtjørn, dan H. J. Overgaard. 2017. Comparison of Two Adult Mosquito Sampling Methods with Human Landing Catches in South-Central Ethiopia. Malaria Journal. 16(1): 1–15.

Yobo, C. M., C. A. M. Sadia-Kacou, M. A. Adja, E. Elanga-Ndille, A. B. Sagna, N. Guindo-Coulibaly, A. et al. 2018. Evaluation of Human Exposure to A edes Bites in Rubber and Palm Cultivations Using an

Immunoepidemiological Biomarker. BioMed Research International: 1-9.

Fustec, B., T. Phanitchat, S. Aromseree, C. Pientong, K. Thaewnongiew, T. Ekalaksananan, et al. 2021. Serological biomarker for assessing human exposure to Aedes mosquito bites during a randomized vector control intervention trial in northeastern Thailand. PLOS Neglected Tropical Diseases. 15(5): 1-22.

Issaq, H. J., dan T. D. Veenstra. 2020. Proteomic and Metabolomic Approaches to Biomarker Discovery. 2nd Ed. San Diego. Elsevier

Ndille, E. E., S. Decoure, G. Damien, F. Mouchet, P. M. Drame, S. Cornelie, H. Noukpo, et al. 2012. First Attempt to Validate Human IgG Antibody Response to Nterm-34 kDa Salivary Peptide as Biomarker for Evaluating Exposure to Aedes aegypti Bites. PLOS Neglected Tropical Diseases.6(11): 1-7.

Bublin, M., H. Breiteneder. 2019. Cross-reactivities of Non-Homologous Allergens. Allergy. 75: 1019-1022.

Dama, E., S. Cornelie, M. Camara, M. B. Somda, A. Poinsignon, H. Ilboudo, et al. 2013. In Silico Identification of a Candidate Synthetic Peptide (Tsgf118-43) to Monitor Human Exposure to Tsetse Flies in West Africa. PLoS Neglected Tropical Diseases 7(9): 1-8.

Li, X., H. W. Yang, H. Chen, J. Wu, Y. Liu, J. F. Wei. 2014. In Silico Prediction of T and B Cell Epitopes of Der f 25 in Dermatophagoides Farinae. International Journal of Genomics. 2014(483905): 1-10.

Ndille, E. E., S. Doucoure, A. Poinsignon, F. O. Mouchet, S. Cornelie, E. D’ortenzio, J. S. B. Dehecq, F. Remoue. 2014. Human IgG antibody response to Aedes aegypti Nterm-34 kDa salivary peptide as an indicator to identify areas at high risk for dengue transmission: A retrospective study in urban settings of Vientiane city, Lao PDR. Tropical Medicine and International Health. 19(5), 576–580.

Doucoure, S., S. Cornelie, S. Patramool, F. Mouchet, E. Demettre, M. Seveno, J. S. Dehecq, et al. 2013. First Screening of Aedes Albopictus Immunogenic Salivary Proteins. Insect Molecular Biology 22(4): 411–23Bublin, M., dan H. Breiteneder. 2019. Cross-reactivities of Non-Homologous Allergens. Allergy. 75: 1019-1022

Hajissa, K., R. Zakaria, R. Suppian, Z. Mohamed. 2015. Design and evaluation of a recombinant multi-epitope antigen for serodiagnosis of toxoplasma gondii infection in humans. Parasites and Vectors. 8(1):1–5

Scheiblhofer, S., J. Laimer, Y. Machado, R. Weiss, J. Thalhamer, 2017. Influence of protein fold stability on immunogenicity and its implications for vaccine design. Expert Review of Vaccines. 16(5): 479–489

MacHado, Y., R. Freier, S. Scheiblhofer, T. Thalhamer, M. Mayr, P. Briza, S. Grutsch, et al. 2016. Fold stability during endolysosomal acidification is a key factor for allergenicity and immunogenicity of the major birch pollen allergen. Journal of Allergy and Clinical Immunology. 137(5): 1525–1534


  • There are currently no refbacks.